Related Experiment Video
Updated: May 16, 2026

Assay Development for High-Throughput Drug Screening Against Mycobacteria
Published on: October 25, 2024
Ceftaroline fosamil: a new cephalosporin active against resistant Gram-positive organisms including MRSA
Mark W Garrison1, Nathan M Kawamura, Mary M Wen
1Washington State University College of Pharmacy, Spokane, WA 99210-1495, USA. garrism@wsu.edu
Abstract:
The growing prevalence of resistant Gram-positive pathogens such as methicillin-resistant Staphylococcus aureus continues to pose a dilemma to clinicians. With strains developing reduced susceptibility to vancomycin, effective and well-tolerated antibiotics to combat these resistant pathogens are needed. Ceftaroline is a new parenteral cephalosporin that has been available in the USA for almost 2 years. Similar to other cephalosporins, it is well tolerated with mostly mild adverse events; however, compared with existing parenteral cephalosporins, ceftaroline has the unique attribute of being bactericidal against resistant Gram-positive aerobes including both hospital- and community-acquired methicillin-resistant S. aureus, S. aureus strains with reduced susceptibility or complete resistance to vancomycin, and resistant Streptococcus pneumoniae including multidrug-resistant strains. Current indications in the USA and Europe include treatment of adults with complicated skin, skin-structure infections and community-acquired pneumonia. This paper will review the properties of ceftaroline, its spectrum of activity, clinical use, safety profile and future role.
Insights
Ceftaroline is a novel cephalosporin antibiotic effective against resistant Gram-positive pathogens, including methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant strains. It offers a new treatment option for serious infections with a favorable safety profile.
Area of Science:
- Infectious Diseases
- Microbiology
- Pharmacology
Background:
- Rising antibiotic resistance in Gram-positive pathogens like MRSA presents a clinical challenge.
- Reduced susceptibility to vancomycin necessitates new therapeutic agents.
- Ceftaroline is a new parenteral cephalosporin with activity against resistant Gram-positive bacteria.
Purpose of the Study:
- To review the properties, spectrum of activity, clinical use, and safety profile of ceftaroline.
- To highlight ceftaroline's unique bactericidal activity against resistant Gram-positive aerobes.
- To discuss the future role of ceftaroline in treating resistant infections.
Main Methods:
- Literature review of ceftaroline's pharmacological properties.
- Analysis of clinical data regarding ceftaroline's efficacy and safety.
- Examination of ceftaroline's spectrum of activity against resistant pathogens.
Main Results:
- Ceftaroline exhibits bactericidal activity against methicillin-resistant Staphylococcus aureus (MRSA).
- It is effective against Staphylococcus aureus strains with reduced susceptibility or resistance to vancomycin.
- Ceftaroline demonstrates activity against resistant Streptococcus pneumoniae, including multidrug-resistant strains.
Conclusions:
- Ceftaroline is a well-tolerated antibiotic with a unique spectrum of activity against key resistant Gram-positive pathogens.
- Current indications include complicated skin and skin-structure infections and community-acquired pneumonia.
- Ceftaroline represents a valuable addition to the therapeutic armamentarium against challenging resistant infections.
Related Concept Videos
Mechanism of Antibiotic Resistance in MRSA
Clinical Significance of Antibiotic Resistance
Inhibitors of Gram-positive Cell Wall Synthesis
Combined Effects of Drugs: Synergism
Such synergistic combinations...
Inhibitors of Bacterial DNA Synthesis
Inhibitors of Bacterial Protein Synthesis

